In the nonsevere and severe disease groups, favorable outcomes were more prevalent among COVID-19 patients receiving oral medication only or oral medication plus insulin than among the insulin-only group (100%, 100% vs. 60% for nonsevere, p=0.020; 97.4%, 100% vs. 73.3% for severe, p=0.034) (Figure 4(a)). The gene discussed is INS; the disease is COVID-19.